The NFL Players Association has called for a full investigation into the medical care of Philadelphia Eagles quarterback Jalen Hurts, who is out for the season with deep vein thrombosis and pulmonary embolisms. The union’s demand follows the discovery of a superficial blood clot on Oct 10, after which the 28-year-old’s condition was found to involve the far more serious deep-vein and lung clots. Reuters and USA Today reported the NFLPA’s call on Oct 21.
The case has drawn intense attention because of both the player’s stature and the nature of the condition. Hurts is one of the NFL’s most prominent quarterbacks, and blood clots in elite athletes raise difficult questions about detection, treatment timelines and the pressures that can surround medical decision-making in professional sport. The NFLPA’s intervention signals that the union believes those questions deserve independent answers.
From a superficial clot to a season-ending diagnosis
According to the reporting, medical staff initially identified a superficial clot on Oct 10. Superficial thrombophlebitis, as the condition is known, involves clots in veins near the skin’s surface and is generally considered less dangerous than clots in the deep venous system. What followed, however, was a diagnosis of deep vein thrombosis, clots in the deep veins, typically of the legs, and pulmonary embolisms, clots that have travelled to the lungs.
Pulmonary embolism is a potentially life-threatening condition that requires immediate treatment, usually with anticoagulant medication, and it ended Hurts’ season. The progression from a superficial finding to a diagnosis involving deep veins and lungs is the sequence of events the NFLPA wants investigated: the union is asking how the initial assessment was made, what monitoring followed and whether opportunities for earlier detection were missed.
Deep vein thrombosis can be insidious. Its symptoms, leg pain, swelling, warmth, are easily mistaken for the routine musculoskeletal complaints of a professional football player. Athletes are also subject to risk factors that the general population is not, including long-distance travel, dehydration and repetitive trauma. These factors make vigilance important and make retrospective scrutiny of medical decisions both necessary and delicate.
Why the union is demanding answers
The NFLPA exists to protect players’ interests, and medical care is among its most sensitive responsibilities. The union has long argued that team medical staffs face an inherent tension: they are employed by the clubs, yet their patients are the players, whose long-term health interests may conflict with a team’s short-term competitive needs. High-profile medical controversies in the past have reinforced the union’s insistence on independent oversight of player health.
A full investigation, as the NFLPA has requested, would examine the chain of medical decisions from the Oct 10 finding onward. It would likely review imaging, consultations, treatment protocols and communications between medical staff, the player and team officials. The goal, from the union’s perspective, is not only to establish what happened in this case but to ensure that the systems for detecting and managing serious conditions are adequate across the league.
The Eagles, like all NFL clubs, operate under league medical protocols that have been strengthened over the years, including requirements for independent neurological consultants and standardised concussion procedures. Blood clots fall outside the most heavily protocolised areas of player health, which is part of why the union’s call for a dedicated investigation carries weight: it suggests a gap that needs examining.
Broader implications for player health
Whatever the investigation finds, the Hurts case is likely to influence how the league thinks about thrombotic conditions in players. If the review identifies shortcomings in detection or escalation, it could lead to new screening guidelines, particularly for players presenting with clot-related symptoms. Professional sports leagues have repeatedly updated their medical standards in response to individual cases that exposed systemic weaknesses.
For Hurts himself, the priority is recovery. Pulmonary embolism treatment typically involves months of anticoagulation, during which contact sport is out of the question. At 28, he is young enough that a full return to elite performance is plausible, but blood clots can recur, and his long-term management will require careful planning between his personal physicians, the team’s medical staff and, now, the scrutiny of an investigation.
The NFLPA’s demand ensures the episode will not be treated as merely unfortunate. In a league where players entrust their bodies to team-employed doctors, the union’s role is to ask the uncomfortable questions, and in the case of Jalen Hurts, it has decided those questions need formal answers.